News : onychomycosis

View:
 

Found press releases

 

FURTHER STUDIES MAY BE REQUIRED FOR MOB-015

2/9/2012 1:59 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be...

MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY

12/9/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
“The agreement is part of our international commercialization of Emtrix®. As...

MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT

11/30/2011 8:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) and Meda have entered into an additional license agreement for Nalox™ - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. The agreement extends Meda's rights to market and sell Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg Derma assumes production and supply responsibility.

MOBERG DERMA AND MEDA SIGN AGREEMENT FOR NALOX IN EUROPE

9/19/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Meda is granted exclusive rights to market and sell Nalox® in a large number of countries in Europe. Moberg Derma assumes production and supply...

MOBERG DERMA REPORTS POSITIVE CLINICAL RESULTS FOR EMTRIX

2/2/2011 4:45 AM EST  -   MOBERG DERMA AB
Moberg Derma AB today reports positive results from a clinical trial of Emtrix. The trial included 75 patients with nail fungus (onychomycosis) and the results showed that 92% of the patients improved after 8 weeks of treatment. Already after 2 weeks, 77% of the patients were improved.
The open clinical trial was conducted at two clinical centers in Sweden during the second half of 2010. The purpose was to...

MOBERG DERMA IS GRANTED PERMIT TO INITIATE PHASE II-TRIAL FOR MOB-015

11/17/2010 2:00 AM EST  -   MOBERG DERMA AB
The Swedish Medical Products Agency has granted Moberg Derma permit to initiate a clinical phase II trial for MOB-015. MOB-015 is Moberg Dermas next generation topical treatment for nail fungus, with fungicidal, keratolytic and emollient properties.
Nail fungus (onychomycosis) chiefly manifests itself in thickening and discoloration of the nails. The disease is common, affecting about 100 million patients in...

Antula launches Nalox™ in the Nordic region– Pharmacies report major demand for ...

9/14/2010 3:00 AM EST  -   MOBERG DERMA AB
Moberg Derma’s market partner in the Nordic countries – Antula Healthcare, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of Nalox™ in the Nordic region. Pharmacies have displayed great interest in Moberg Derma’s product Nalox™ – a treatment for discoloured and damaged nails caused by nail fungus or nail psoriasis.

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT WITH PERRIGO

8/13/2010 9:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB, Sweden, today announced a commercial agreement with Perrigo Company that covers distribution in Israel for Moberg Derma’s novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration and promotion in...

MOBERG DERMA AND MEDICAL FUTURES INC SIGNS COMMERCIAL AGREEMENT FOR NAIL PRODUCT...

4/21/2010 3:35 AM EST  -   MOBERG DERMA AB
Moberg Derma AB, Sweden and Medical Futures Inc, Canada (“MFI”), today announced a commercial license agreement. The license covers distribution in Canada for Moberg Derma’s novel topical nail product – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while MFI will be responsible for promotion in the...

MOBERG DERMA OBTAINS APPROVAL FOR NOVEL TREATMENT FOR NAIL DISEASES

4/12/2010 3:31 AM EST  -   MOBERG DERMA AB
Moberg Derma AB today announced that CE-mark has been granted for the company’s first approved medical device product, used for the treatment of discolored and damaged nails, for example caused by nail fungus (onycomycosis) or nail psoriasis. The CE mark provides authorization to market and sell the product in the EU/EEA.
“The approval is a result of focused development work during several years and is an...